Skip to content

Construction and Application of UMS-based Pharmaceutical Care System

Construction and Application of UMS-based Pharmaceutical Care System

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500112342
Enrollment
Unknown
Registered
2025-11-12
Start date
2024-12-01
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ischemic stroke

Interventions

Experimental group:On the basis of the control group, personalized medication plan was formulated for patients before discharge, pharmacists were given pharmaceutical care, adverse reaction feedback a
Control group:Discharge management of secondary prevention of ischemic stroke based on routine medical care was given, including lifestyle intervention such as health education, diet and exercise guid

Sponsors

Xiangya Hospital Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
55 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Age >=55 years; 2.Patients who have experienced ischemic stroke for the first time in clinical practice and who have experienced ischemic stroke recently (within 3-6 months).(2) The diagnosis depends on CT or MRI examination of the head, and cerebral hemorrhage or non-ischemic nervous system diseases are excluded, and the diagnostic criteria of China Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke are met; 3.Presence of one or more vascular risk factors such as hypertension, diabetes, dyslipidemia; 4.MRS score 0-3; 5.Patients or their family members have normal communication and cognitive skills, can use mobile phones, WeChat and other Internet tools;and are willing to sign informed consent forms.

Exclusion criteria

Exclusion criteria: 1.Radiological evidence suggests a cerebral hemorrhage; 2.A definite cause of stroke or transient ischemic attack unrelated to atherosclerosis (e.g. carotid dissection or perivascular procedural stroke); 3.Stroke due to severe cardiogenic embolism; 4.Serious comorbidities or unstable conditions (e.g. congestive heart failure, severe cardiogenic embolism, respiratory failure, renal failure, severe liver dysfunction, or malignancy that may die within 2 years); 5.Hemorrhagic stroke and fatal stroke were excluded; 6.Severe memory or behavior disorders requiring routine care.

Design outcomes

Primary

MeasureTime frame
Medication compliance;

Secondary

MeasureTime frame
Patient's knowledge of medication;

Countries

China

Contacts

Public ContactXiao Jian

Xiangya Hospital Central South University

admanoas@163.com+86 139 7316 8895

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026